Premium
Establishment and characterisation of a human clear cell sarcoma model in nude mice
Author(s) -
Crnalic Sead,
Panagopoulos Ioannis,
Boquist Lennart,
Mandahl Nils,
Stenling Roger,
Löfvenberg Richard
Publication year - 2002
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.10588
Subject(s) - sarcoma , nude mouse , biology , doubling time , pathology , vimentin , transplantation , flow cytometry , immunohistochemistry , in vivo , cell culture , melanoma , cancer research , microbiology and biotechnology , immunology , medicine , genetics , surgery
We have established a new experimental model of human clear cell sarcoma, UM‐CCS1, using serial subcutaneous transplantation of intact tumour tissue in nude mice. The heterotransplanted nude mouse tumours retained characteristic morphological features of the primary clear cell sarcoma. Immunohistochemical analysis showed the retained expression patterns of S‐100 protein, melanoma‐associated antigen HMB‐45 and vimentin in the xenografts as compared to the primary tumour. DNA index showed low variations both between the xenografts in the same passage and between the serial passages. Cytogenetic analysis of the primary tumour and the xenografts showed the unbalanced translocation der(6)t(6;12)(p23;q13). Based on the combined genetic data a reasonable interpretation of our findings is that there was a complex chromosomal rearrangement resulting in a cytogenetically cryptic EWS‐ATF1 fusion gene. Analysis of cell kinetics using in vivo incorporation of iododeoxyuridine and flow cytometry showed generally short potential doubling time (T pot ) of the xenografts. Volume doubling time showed low variations without correlation with T pot . The retained phenotypic and genotypic characteristics of the primary tumour and the morphological and structural stability over time makes the model suitable for studies on the tumour biology and treatment of clear cell sarcoma. © 2002 Wiley‐Liss, Inc.